Nuvalent, Inc., a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, has appointed Christy Oliger to its Board of Directors. Oliger, who brings over 30 years of experience in the pharmaceutical and biotechnology industry, was previously the Senior Vice President of the Oncology Business Unit at Genentech. Her appointment comes as Nuvalent prepares for potential commercialization of its novel kinase inhibitors in 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvalent Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE13610) on June 18, 2025, and is solely responsible for the information contained therein.